The Role Of “Il 10 (-2 1082 A/G)” Promoter Polymorphism In Ovarian Epithelial Cancer Pathogenesis
DOI:
https://doi.org/10.56988/chiprof.v1i1.3Keywords:
Ovarian Epithelial Cancer, Polymorphism, IL 10 Gene Promoter, (-1082 A/G)Abstract
Ovarian cancer (ovarian cancer) is the abnormal development of cells in one or two ovaries. Many cytokine functions are related to the development of immunological and inflammatory responses that play essential roles in cancer pathogenesis. Among the cytokines, interleukin 10 (IL-10) is an anti-inflammatory cytokine involved in the downregulation of cytotoxic and inflammatory cell-mediated responses. This study aims to determine the relationship between the Gene Promoter Polymorphism Interleukin 10 (-1082 A/G) with the incidence of ovarian epithelial cancer. This research is an observational analytical study conducted at the Molecular Biology Laboratory in Palembang City in October-December 2021. The number of samples was 60 respondents consisting of 30 case groups and 30 control groups. Data were obtained by genotype and allele using PCR-RFLP, which was then analyzed by Chi-Square test to determine whether there was a relationship. The results showed no significant relationship between the promoter of the IL 10 gene polymorphism
(-1082 A/G) and the incidence of ovarian epithelial cancer.
References
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209–49.
Pangribowo S. Beban Kanker di Indonesia. Pus Data Dan Inf Kesehat Kementeri Kesehat RI. 2019;1–16.
Kusumawaty Ira, Yunike Yunike EI. The complexity of family stigma living with mental illness patients. 2019;8(4).
Wiyanti S, Kusumawaty I. Save Human Life through Basic Life Support Training. 2021;
Amri L. Angka Kematia Pasien Obstetri dan Ginekologi pada Tahun 2012-2016 di Rumah Sakit Haji Adam Malik Medan. 2017; Available from: http://repositori.usu.ac.id/handle/123456789/3494
Flaum N, Crosbie EJ, Edmondson RJ, Smith MJ, Evans DG. Epithelial ovarian cancer risk: A review of the current genetic landscape. Clin Genet. 2020;97(1):54–63.
Sapalidis K, Machairiotis N, Zarogoulidis P, Vasilakaki S, Sardeli C, Koimtzis G, et al. Genes’ interactions: A major contributor to the malignant transformation of endometriosis. Int J Mol Sci. 2019;20(8).
Trifunović J, Miller L, Debeljak Ž, Horvat V. Pathologic patterns of interleukin 10 expression - A review. Biochem Medica. 2015;25(1):36–48.
Abildgaard C, Do Canto LM, Steffensen KD, Rogatto SR. Long Non-coding RNAs Involved in Resistance to Chemotherapy in Ovarian Cancer. Front Oncol. 2020;9.
Hishida A, Okugawa Y, Morimoto Y, Shirai Y, Okamoto K, Momokita S, et al. Genetic influence of cytokine polymorphisms on the clinical outcome of Japanese gastrointestinal cancer patients in palliative care. Oncol Lett. 2019;17(1):623–9.
WHO. DISTRIBUTION : GENERAL Summary Surveillance of risk factors for noncommunicable diseases The WHO STEPwise approach Noncommunicable Diseases and Mental Health. World Heal Organ. 2001;
Pome G, Kusumawaty I, Yunike, Septiana LR. Overview of the Implementation of Health Care Education in Diabetes Mellitus Patients with Diet Nonconformity. Proc First Int Conf Heal Soc Sci Technol (ICoHSST 2020). 2021;521(ICoHSST 2020):68–72.
Kusumawaty I, Yunike, Jawiah, Rehana. Family resilience in caring for drug addiction. Gac Sanit [Internet]. 2021;35:S491–4. Available from: https://doi.org/10.1016/j.gaceta.2021.10.079
Kusumawaty Ira, Yunike P. The Complexity of Caring for People with Mental Disorders: Family Challenges in Contributing to Horticultural Therapy. Pakistan J Med Heal Sci. 2020;14(2):1442–6.
Reid BM, Permuth JB, Ann Chen Y, Fridley BL, Iversen ES, Chen Z, et al. Genome-wide analysis of common copy number variation and epithelial ovarian cancer risk. Cancer Epidemiol Biomarkers Prev. 2019;28(7):1117–26.
Grant DJ, Manichaikul A, Alberg AJ, Bandera E V., Barnholtz-Sloan J, Bondy M, et al. Evaluation of vitamin D biosynthesis and pathway target genes reveals UGT2A1/2 and EGFR polymorphisms associated with epithelial ovarian cancer in African American Women. Cancer Med. 2019;8(5):2503–13.
Lheureux S, Gourley C, Vergote I, Oza AM. Epithelial ovarian cancer. Lancet [Internet]. 2019;393(10177):1240–53. Available from: http://dx.doi.org/10.1016/S0140-6736(18)32552-2
Lisio MA, Fu L, Goyeneche A, Gao ZH, Telleria C. High-grade serous ovarian cancer: Basic sciences, clinical and therapeutic standpoints. Int J Mol Sci. 2019;20(4).
Jia G, Lu Y, Wen W, Long J, Liu Y, Tao R, et al. Evaluating the utility of polygenic risk scores in identifying high-risk individuals for eight common cancers. JNCI Cancer Spectr. 2020;4(3):1–8.
Małgorzata SW, Nedoszytko B, Olszewska B, Roszkiewicz J, Glen J, Zabłotna M, et al. The role of polymorphism of interleukin-2, -10, -13 and TNF-α genes in cutaneous T-cell lymphoma pathogenesis. Postep Dermatologii i Alergol. 2016;33(6):429–34.
Sharma T, Banerjee BD, Thakur GK, Guleria K, Mazumdar D. Polymorphism of xenobiotic metabolizing gene and susceptibility of epithelial ovarian cancer with reference to organochlorine pesticides exposure. Exp Biol Med. 2019;244(16):1446–53.
Salima S, Gandamihardja S, Harsono ALIB. Korelasi antara Ekspresi Tumor Infiltrating. Indones J Cancer. 2016;10(2):43–7.
Corona RI, Seo JH, Lin X, Hazelett DJ, Reddy J, Fonseca MAS, et al. Non-coding somatic mutations converge on the PAX8 pathway in ovarian cancer. Nat Commun [Internet]. 2020;11(1):1–11. Available from: http://dx.doi.org/10.1038/s41467-020-15951-0
Antoneeva II, Abakumova T V., Dolgova DR, Gening TP, Pirmamedova SS, Myasnikova DF, et al. Cytokine Status of Serum in Ovarian Cancer Patients with Different Tumor Neoadjuvant Chemotherapy Response. Anticancer Agents Med Chem. 2017;17(9):1251–5.
Du GH, Wang JK, Richards JR, Wang JJ. Genetic polymorphisms in tumor necrosis factor alpha and interleukin-10 are associated with an increased risk of cervical cancer. Int Immunopharmacol [Internet]. 2019;66(32):154–61. Available from: https://doi.org/10.1016/j.intimp.2018.11.015
Hu W, Wang G, Huang D, Sui M, Xu Y. Cancer immunotherapy based on natural killer cells: Current progress and new opportunities. Front Immunol. 2019;10(MAY):1–16.
Buckley MA, Woods NT, Tyrer JP, Mendoza-Fandiño G, Lawrenson K, Hazelett DJ, et al. Functional analysis and fine mapping of the 9p22.2 ovarian cancer susceptibility locus. Cancer Res. 2019;79(3):467–81.
Chan W, Lee M, Yeo ZX, Ying D, Grimaldi KA, Pickering C, et al. Development and validation of next generation sequencing based 35-gene hereditary cancer panel. Hered Cancer Clin Pract. 2020;18(1):1–8.
Giovanni Galizia; Slike Sachse, Angelika, Rappert and Menzel R. 140100037.pdf. 1999.
Rachman T. 済無No Title No Title No Title. Angew Chemie Int Ed 6(11), 951–952. 2018;10–27.
Sciences H. 済無No Title No Title No Title. 2016;4(1):1–23.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Siti Fatimah, Rika Hairunisyah
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
